World Recycling Center Spółka Akcyjna (KRS 0000698030, NIP 9542782699) is a Polish company, headquartered in Sosnowiec, Śląskie voivodeship. World Recycling Center operates in: Research and experimental development on biotechnology (PKD 72.11.Z). Industry: Research and development. The company has been listed in the National Court Register since October 4, 2017. World Recycling Center's most recently reported net revenue was 8.1 K PLN for 2024.
Negative equity
Negative equity in 6 of 7 available reporting years.
No arrears identified in the analysed sources
No arrears or bankruptcy proceedings identified in the analysed sources.
Business profile - World Recycling Center
Identity
- Name
- World Recycling Center Spółka Akcyjna
- Legal form
- SPÓŁKA AKCYJNA
- Founded
- October 4, 2017
- Registry status as of
- July 16, 2026
- Latest entry
- July 16, 2026
- Founding act
- 31.07.2017R. REP. A 4049/2017, NOTARIUSZ WOJCIECH WYSOWSKI KANCELARIA NOTARIALNA W SIEMIANOWICACH ŚLĄSKICH
Articles of association history (2)
- July 31, 2017: 31.07.2017R. REP. A 4049/2017, NOTARIUSZ WOJCIECH WYSOWSKI KANCELARIA NOTARIALNA W SIEMIANOWICACH ŚLĄSKICH
- July 19, 2021: 19.07.2021R., REP A NR 1048/2021,NOTARIUSZ HANNA DOLNICKA-WYBRANIEC, KANCELARIA NOTARIALNA W KATOWICACH PRZY UL.KOŚCIUSZKI 55/8, , ZMIANA § 1 UST.4
Activities
Other activities
Address and contact
- Address
- ALEJA JÓZEFA MIRECKIEGO, 15, 5, 41-209, SOSNOWIEC, POLSKA
- Voivodeship
- ŚLĄSKIE
- District
- SOSNOWIEC
- Not disclosed in the registry
- Website
- WWW.WORLDRECYCLINGCENTER.COM
- E-delivery address
- AE:PL-88321-66107-AWJTH-20
Risk and payment profile - World Recycling Center
Credibility rating
24.2 / 100
Poor credibility
Insolvency risk
Very high
Significant formal threat
Closure risk
37
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organisational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
0
0/9 yrs
Board changes
2
2/9 yrs
PKD changes
0
0/9 yrs
Name changes
0
0/9 yrs
Data from 9 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: E (24/100)
Trend: deteriorating (-8.8 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2018–2024
Current: 238.31 PLN
Safe: 23.83 PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - World Recycling Center
Founded
October 4, 2017
8 years in operation
Legal form
SPÓŁKA AKCYJNA
Registry: RejP
Headquarters
SOSNOWIEC
ŚLĄSKIE
Primary PKD
72.11.Z
Research and experimental development on biotechnology
Share capital
100.0 K PLN
Shareholders
1
shareholder
Board
1 person
Sup. board: 3
Filed years
7 years
2018–2024 · profitable: 3/7
Registry entries
35
latest: July 16, 2026
Risk signals
Revenue
8.1 K PLN
2024
Net profit
931.59 PLN
2024
Assets
153.7 K PLN
2024
Equity
-33.1 K PLN
2024
EBITDA
1.1 K PLN
2024
Valuation
4.0 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - World Recycling Center.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase on BCX-CM-J – potentially Europe's first veterinary cell-therapy drug based on mesenchymal stem cells, for dogs with osteoarthritis. Responses to the EMA's final questions are due in May 2026; a CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. A pre-commercial biotech: it closed 2024 with a PLN 14.9m loss on zero revenue and PLN 33.6m of cash at year-end. Trigon DM maintains a buy rating with a PLN 127.2 price target.
News
Captor Therapeutics: PLN 36m of cash at 30 September 2025, runway to mid-2026 – clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) – a pre-commercial biotech specialising in targeted protein degradation (TPD) – closed Q3 2025 with PLN 36m of cash and grants securing funding to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I, with the first patient dosed at the Barcelona Clinic Liver Cancer. CT-03, an MCL-1 degrader, is close to clinical entry. Without a new R&D partnership or share issue in 2026, the company will need additional financing.
